Search VRDN
Viridian Therapeutics, Inc.\DE
Nasdaq · CIK 1590750
Last close19.4
Daily change+0.41 (2.16%)
10 Years gain-82.33%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
VRDN · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
20.2Momentum
n/aAcceleration
n/aConfidence
62.0Annual Revenue5
Quarterly Revenue18
Annual CFO13
Balance SheetMissing
RankingLimited
Score Breakdown
Growth11.1 / 25
Quality8.1 / 25
Capital Efficiency0.0 / 20
Balance Sheet0.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
No positive signals calculated.
Warnings
Receivables anomaly · MEDIUMAccounts receivable growth is materially above revenue growth.
Key Metrics
Revenue Growth TTM251.92%OK
Revenue CAGR 3Y-14.85%OK
Gross Marginn/aMISSING
Operating Marginn/aMISSING
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROICn/aMISSING
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Yn/aINSUFFICIENT_HISTORY
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | n/a | $70.85M | -$363.40M | -$276.39M | -$276.89M | n/a | n/a | n/a | n/a | n/a |
| 2025 FY Dec 31, 2024 | n/a | $302,000.00 | -$299.04M | -$232.32M | -$232.83M | n/a | n/a | n/a | n/a | n/a |
| 2025 FY Dec 31, 2023 | n/a | $314,000.00 | -$254.45M | -$184.17M | -$185.07M | n/a | n/a | n/a | n/a | n/a |
| 2024 FY Dec 31, 2022 | n/a | $1.77M | -$134.30M | -$93.84M | -$94.64M | n/a | n/a | n/a | n/a | n/a |
| 2023 FY Dec 31, 2021 | n/a | $2.96M | -$79.73M | -$54.58M | -$54.92M | n/a | n/a | n/a | n/a | 11.92M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $9.24M | sum latest 4 fiscal quarters Revenue | OK | 0001590750-18-000006, 0001590750-17-000010 |
| Revenue Growth TTM | 251.92% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001590750-18-000006, 0001590750-17-000010 |
| Revenue CAGR 3Y | -14.85% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001590750-18-000006 |
| Revenue CAGR 5Y | n/a | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | INSUFFICIENT_HISTORY | 0001590750-18-000006 |
| Gross Profit CAGR 3Y | n/a | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | INSUFFICIENT_HISTORY | derived |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001590750-18-000012 |
| Cash / Debt | 0x | (Cash + Short-term Investments) / Total Debt | OK | derived |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |
| Dividend Payout Ratio | n/a | Cash dividends paid / Net income | NOT_MEANINGFUL | derived |
| Diluted EPS TTM | n/a | Net income TTM / Diluted shares | NOT_MEANINGFUL | derived |
| Gross Margin Delta 1Y | n/a | GrossMargin_current - GrossMargin_prior_year | INSUFFICIENT_HISTORY | derived |
| Gross Margin Delta 3Y | n/a | GrossMargin_current - GrossMargin_3Y_ago | INSUFFICIENT_HISTORY | derived |